AstraZeneca's Datroway extends survival in aggressive breast cancer

AstraZeneca and Daiichi Sankyo's new breast cancer drug, Datroway, has shown significant promise in extending survival for patients with triple-negative breast cancer. In a late-stage trial, patients treated with Datroway had a median overall survival of 23.7 months compared to 18.7 months for those receiving chemotherapy. The drug, which received U.S. approval earlier this year, delivers chemotherapy directly to tumor cells, reducing toxicity. Its success could position it as a competitor to Gilead's Trodelvy, with potential to treat 90% of women with breast cancer.